Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
8
NGVT Quote, Financials, Valuation and Earnings
Last price:
$40.77
Seasonality move
:
-3.29%
Day range:
$40.14 - $41.45
52-week range:
$30.90 - $56.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.00x
P/B ratio:
6.91x
Volume:
953.1K
Avg. volume:
265.2K
1-year change:
-10.31%
Market cap:
$1.5B
Revenue:
$1.7B
EPS (TTM):
-$15.53
Analysts' Opinion
-
Consensus RatingIngevity has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $54.25, Ingevity has an estimated upside of 32.97% from its current price of $40.80.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $45.00 representing -10.29% downside risk from its current price of $40.80.
Fair Value
-
According to the consensus of 3 analysts, Ingevity has 32.97% upside to fair value with a price target of $54.25 per share.
NGVT vs. S&P 500
-
Over the past 5 trading days, Ingevity has underperformed the S&P 500 by -9.17% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ingevity does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ingevity revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Ingevity reported revenues of $376.9M.
Earnings Growth
-
Ingevity earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Ingevity reported earnings per share of -$2.95.
Enterprise value:
2.8B
EV / Invested capital:
1.66x
Price / LTM sales:
1.00x
EV / EBIT:
--
EV / Revenue:
1.92x
PEG ratio (5yr expected):
--
EV / Free cash flow:
100.21x
Price / Operating cash flow:
52.14x
Enterprise value / EBITDA:
42.40x
Gross Profit (TTM):
$412.3M
Return On Assets:
-22.65%
Net Income Margin (TTM):
-38.11%
Return On Equity:
-116.58%
Return On Invested Capital:
-28.61%
Operating Margin:
22.42%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.6B | $1.7B | $1.5B | $446M | $376.9M | |
| Gross Profit | $569.7M | $517.8M | $412.3M | $129M | $129.9M | |
| Operating Income | $348.4M | $289.8M | $213.6M | $81.2M | $84.5M | |
| EBITDA | $450M | $370.4M | -$486.2M | $86.5M | -$86.8M | |
| Diluted EPS | $5.81 | $3.42 | -$15.53 | $0.69 | -$2.95 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $601M | $720.3M | $645.1M | $734.5M | $636.8M | |
| Total Assets | $2.3B | $2.4B | $2.3B | $2.8B | $2.2B | |
| Current Liabilities | $178.9M | $247.6M | $290.3M | $305.1M | $360.8M | |
| Total Liabilities | $1.6B | $1.8B | $1.7B | $2B | $2B | |
| Total Equity | $617M | $644.5M | $633.9M | $718.7M | $214.5M | |
| Total Debt | $1.3B | $1.3B | $1.2B | $1.5B | $1.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $291.2M | $257.4M | $110.3M | $105.2M | $46.5M | |
| Cash From Investing | -$199.9M | -$459.8M | -$76.2M | -$32.3M | -$17.4M | |
| Cash From Financing | -$277.7M | $219.6M | $20.9M | -$53.3M | -$6.3M | |
| Free Cash Flow | $160.5M | $127.6M | $28.4M | $71.7M | $28.5M | |
NGVT
Sector
Market Cap
$1.5B
$18.6M
Price % of 52-Week High
72.48%
57.24%
Dividend Yield
0%
0%
Shareholder Yield
0.4%
1.61%
1-Year Price Total Return
-10.31%
-16.67%
Beta (5-Year)
1.622
1.065
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$43.89
200-day SMA
Sell
Level
$43.59
Bollinger Bands (100)
Buy
Level
34.94 - 45.16
Chaikin Money Flow
Sell
Level
-6.5M
20-day SMA
Sell
Level
$46.29
Relative Strength Index (RSI14)
Sell
Level
34.56
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-93.0599
50-day SMA
Sell
Level
$42.68
MACD (12, 26)
Sell
Level
-0.61
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
9.9M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.9352)
Sell
CA Score
(Annual)
Level (-1.2341)
Buy
Beneish M-Score
(Annual)
Level (-2.9195)
Sell
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-19.3105)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.
Stock Forecast FAQ
In the current month, NGVT has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The NGVT average analyst price target in the past 3 months is $54.25.
-
Where Will Ingevity Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ingevity share price will rise to $54.25 per share over the next 12 months.
-
What Do Analysts Say About Ingevity?
Analysts are divided on their view about Ingevity share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ingevity is a Sell and believe this share price will drop from its current level to $45.00.
-
What Is Ingevity's Price Target?
The price target for Ingevity over the next 1-year time period is forecast to be $54.25 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is NGVT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ingevity is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of NGVT?
You can purchase shares of Ingevity via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ingevity shares.
-
What Is The Ingevity Share Price Today?
Ingevity was last trading at $40.77 per share. This represents the most recent stock quote for Ingevity. Yesterday, Ingevity closed at $40.80 per share.
-
How To Buy Ingevity Stock Online?
In order to purchase Ingevity stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
